NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-075-2000-0-JP-05 NITRIC OXIDE Releasing Metallic Medical Devices JP National Stage 2001-581880 Expired
NICHD E-023-2002-0-US-02 Methods for Preparing Bacillus Anthracis Protective Antigen For Use In Vaccines US ORD 10/290,712 7763451 Issued PDF
NHLBI E-325-2001-2-CA-03 Production of Adeno-Associated Virus in Insect Cells CA National Stage 2467959 Expired
NHLBI E-325-2001-2-EP-04 Production of Adeno-Associated Virus in Insect Cells EP National Stage 02795604.4 Expired
NHLBI E-325-2001-2-AU-05 Production of Adeno-Associated Virus in Insect Cells AU National Stage 2002360355 Expired
NHLBI E-325-2001-2-PCT-01 Production of Adeno-Associated Virus in Insect Cells PCT PCT COMB PCT/US2002/035829 Expired
NIAID E-278-2001-0-PCT-02 Hepatitis E Virus Clones and Methods of Their Use PCT PCT PCT/US02/36096 Expired
NIDCR E-308-2003-2-US-01 EUKARYOTIC TRANSLATION INITIATION FACTOR 5A (eIF-5A) and THEIR USE TO CONTROL PROLIFERATION OF CELLS US 60/424,978 Abandoned
NCI E-294-2002-0-US-01 A New Target for Angiogenesis and Anti-angiogenesis Therapy US 60/425,018 Abandoned
NCI E-249-2002-0-US-01 Smallpox Vaccine Regimen US 60/425,148 Abandoned
NCI E-209-2002-0-US-01 Method for Separating Recombinant Immunotoxin US 60/425,170 Abandoned
NIAID E-356-2001-0-PCT-02 Anti-Hepatitis A Virus Antibodies PCT PCT PCT/US02/036077 Expired
NCI E-339-2001-0-US-02 Filtration of Red Blood Cells US ORD 10/289,686 Abandoned
NHLBI E-320-2002-0-US-01 Detection of Mutational Frequency in Human Bone Marrow By Sequencing of Mitochondrial DNA From Single Cells US 60/424,515 Abandoned
NCI E-195-2001-2-PCT-02 Chemoprotectant Compositions PCT PCT PCT/US2002/035437 Expired
NIAID E-250-2002-0-US-01 Safer Attentuated Virus Vaccines with Missing or Diminished Latency of Infection US 60/423,603 Abandoned
NCI E-248-2002-0-US-01 "Methods and Composition for the Diagnosis of Neuroendocrine Lung Cancer" US 60/423,380 Abandoned
NCI E-011-2002-0-US-02 Semaphorin 3 B(SEMA3B) as Diagnostic And Therapeutic Agent For Human Cancer US CON 10/285,351 7781413 Abandoned PDF
NCI E-360-2001-0-PCT-02 Generation And Use of Tc1 And Tc2 Cells PCT PCT PCT/US02/35240 Expired
NCI E-232-2002-0-US-01 9-10InsC in 5'UTR May Be Useful Polymorphism in Identification of Melanoma Metastasis US 60/422,821 Abandoned
NCI E-233-2002-0-US-01 Method of Distinguishing Epithelioid Melanaoma From Fibroblastoid Melanoma US 60/422,733 Abandoned
NCI E-044-1991-2-US-02 TRUNCATED HEPATOCYTE GROWTH FACTOR VARIANTS US DIV 10/283,769 7605127 Expired PDF
NIAID E-240-2002-0-US-01 HTLV-1-Cell Binding & Inhibition US 60/422,803 Abandoned
NCI E-025-2003-0-US-01 Methods for Prophylaxis and Treatment of HER-2/neu Tumors US 60/422,395 Abandoned
CC E-008-2003-0-US-01 Scavenger Receptor B1 Targeting For The Treatment Of Infection, Sepsis And Inflammation US 60/422,105 Abandoned
NINDS E-291-1999-0-US-02 EFFICIENT GENERATION OF MIDBRAIN NEURONS FROM MOUSE EMBRYONIC STEM CELLS US ORD 10/258,975 Abandoned
NIAID E-285-2002-0-US-01 Lutzomyia Longipalpis polypeptides and methods of use US 60/422,303 Abandoned
NCI E-090-2000-1-US-06 NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN NY ESO-1 US National Stage 10/182,506 7619057 Abandoned PDF
NICHD E-069-2000-3-US-05 METHODS OF MAKING, USING AND PHARMACEUTICAL FORMULATIONS COMPRISING 7 ALPHA,11BETA-DIMETHYL-17BETA-HYDROXYLATIONS-4,14 DIEN-3-ONE AND 17... US National Stage 10/281,794 7196074 Abandoned PDF
NCI E-157-2000-0-US-03 Immunogenicity Using a Combination of DNA and Vaccinia Virus Vector Vaccines US National Stage 10/258,570 7094408 Expired PDF
NCI E-336-2001-0-PCT-01 Amyloid B is a Ligand For FPR Class Receptors PCT PCT PCT/US02/34455 Expired
NCI E-289-2002-0-US-01 Methods to Prevent Tumor Recurrence by Blockade of TGF-Beta US 60/421,286 Abandoned
NCI E-342-2002-0-US-01 B-Defensins as activators of Dendritic Cells US 60/421,488 Abandoned
NIDDK E-171-2003-0-KR-01 Adenosine Derivatives As A3 Receptor Agonists KR ORD 10-2002-0065441 Abandoned
NIAID E-337-2001-0-IE-08 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection IE EP 02799169.4 Abandoned
NIAID E-337-2001-0-DE-06 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection DE EP 02799169.4 Abandoned
NIAID E-337-2001-0-FR-05 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection FR EP 02799169.4 Abandoned
NIAID E-337-2001-0-EP-03 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection EP National Stage 02799169.4 Abandoned
NIAID E-337-2001-0-GB-07 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection GB EP 02799169.4 Abandoned
NIAID E-337-2001-0-PCT-01 Immunconjugates Comprising CD4 and Immunogobulin Molecules for the Treatment of HIV Infection PCT PCT PCT/US02/34393 Expired
NIAID E-221-1997-0-US-06 CHIMERIC VACCINE AGAINST TICK-BORNE ENCEPHALITIS VIRUS US CON 10/279,130 6660273 Abandoned PDF
NIDDK E-064-2004-0-EP-14 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment EP DIV 10165256.8 Expired
NIDDK E-064-2004-0-PL-06 The Use Of Leptin For Treating Human Lipotrophy PL National Stage PL374301 Expired
NIDDK E-064-2004-0-CA-07 The Use Of Leptin For Treating Human Lipotrophy CA National Stage 2464277 Expired
NIDDK E-064-2004-0-ES-19 USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT ES EP 02793811.7 Expired
NIDDK E-064-2004-0-SE-24 USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT SE EP 02793811.7 Expired
NIDDK E-064-2004-0-EP-08 USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT EP National Stage 02793811.7 Expired
NIDDK E-064-2004-0-CH-16 The Use Of Leptin For Treating Human Lipoatrophy CH EP 02793811.7 Expired
NIDDK E-064-2004-0-GB-21 USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT GB EP 02793811.7 Expired
NIDDK E-064-2004-0-NL-23 USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT NL EP 02793811.7 Expired